1030825-20-7,
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene,
2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene,
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl]thiophene,
AK101613,
2-(4-fluorophenyl)-5-[(5-bromo-2-methylphenyl)methyl]thiophene,
Thiophene, 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)-,
A1-00243,
2-((5-bromo-2-methylphenyl)methyl)-5-(4-fluorophenyl)thiophene,
VLRIERSBZHUCOW-UHFFFAOYSA-N,
C18H14BrFS,
Canagliflozin Intermediate II,
SCHEMBL154701,
THI043,
THI064,
CTK8B9643,
DTXSID10677368,
BCP07730,
CS-M1889,
ANW-62836,
BBL103020,
MFCD21496340,
STL556829,
ZINC71973419,
AKOS016004335,
ACN-028594,
AS06217,
CM13888,
QC-2696,
AC-26308,
AS-20009,
BC600262,
PC448035,
SY112941,
AB0095332,
AJ-118995,
AX8233152,
TC-151581,
4CH-021688,
FT-0697204,
ST24039490,
Z3521,
MFCD21496340 (97%),
2-(5-Bromo-methyl Benzyl)-5-(4-fluorophenyl)thiophene,
2-[(5-Bromo-2-methyl-phenyl)methyl]-5-(4-fluorophenyl)thiophene,
Thiophene,2-[(5-broMo-2-Methylphenyl)Methyl]-5-(4-fluorophenyl)-,
Canagliflozin impurity C,
CS-AQ-00192,
ACN-028594-2,
Methyl 1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucopyranoside,
1030825-21-8,